Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tiny zinc particles stop a deadly hospital superbug?

NCT ID NCT06628076

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study investigates whether zinc oxide nanoparticles can inhibit the growth and biofilm formation of Acinetobacter baumannii, a bacterium that causes severe hospital-acquired infections like pneumonia and bloodstream infections. Researchers will collect samples from 150 patients in Sohag University Hospitals, identify A. baumannii strains, and test their antibiotic resistance. In the lab, they will expose these bacteria to different concentrations of zinc oxide nanoparticles to see if the particles can disrupt biofilms and affect genes related to resistance and biofilm formation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Zinc oxide nanoparticles (ZnO NPs) tested in the lab against A. baumannii bacteria
What this could lead to
If effective, ZnO NPs could become a new tool against drug-resistant A. baumannii infections, potentially reducing mortality in hospitals.
What could go wrong
This is a lab-based study, not a clinical treatment trial. Results may not translate to real-world use, and safety in humans is not yet tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Oct 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will be carried out at Department of Medical Microbiology and Immunology, Sohag Faculty of Medicine and Sohag University Hospitals.

Ages

Up to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients suffering from infections that can be caused by A. baumannii. Exclusion Criteria: * All patients suffering from infections that aren\'t caused by A. baumannii.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infections, nosocomial are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nosocomial infection respiratory tract infectious disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infections, nosocomial Infections, respiratory tract

Contacts and locations

Locations

  • Sohag university, Faculty of medicine

    Sohag, 534568, Egypt